SPM International Launches SPM Academy Inc. – a New Global Center for ISO-Compliant Vibration Training and Certification
3.11.2025 09:00:00 CET | Business Wire | Press Release
SPM Instrument, a global leader in condition monitoring, is taking the next step in its mission to empower industries with knowledge and tools that ensure reliability and performance. SPM Academy Inc., based in the U.S., will serve as a worldwide hub for vibration training and certification, strengthening industrial reliability expertise across sectors.
Led by Bill Partipilo, CEO of SPM Instrument North America, the Academy builds on SPM’s long tradition of innovation and customer support through learning.
“Our new global training center gives maintenance and reliability professionals the chance to develop their skills through interactive, high-quality course materials – in their local language, on a platform or location that suits them,” said Partipilo.
SPM Academy combines practical exercises, simulators, and real-world case studies for a dynamic learning experience. Training and certification follow ISO/IEC 17024, ISO 18436-1, and ISO 18436-2. The SPM Academy Certification Center is currently seeking accreditation through the ANSI National Accreditation Board. Accreditation ensures that certification meets independent, internationally recognized standards.
Christer Larsson and Dennis Swanepoel, both Vibration CAT IV certified, develop and teach the courses, bringing deep industry insight to the classroom.
Launching in November 2025, SPM Academy Inc. will offer courses in English, Spanish, and Swedish, available in classrooms, online, or on-site. The first programs – Vibration Analysis CAT I and CAT II – start January 1, 2026, followed by CAT III and CAT IV. Each concludes with an optional ISO 18436-2 certification exam conducted impartially by the Academy’s Certification Center. Course details will be available at spmacademy.com.
SPM Academy is also inviting independent training centers worldwide to explore collaboration and accreditation opportunities by contacting info@spmacademy.com.
More than a training provider, SPM Academy represents a global community dedicated to advancing maintenance and reliability competence – preparing industry professionals to meet the condition monitoring challenges of tomorrow.
About SPM International
Founded in 1970 and headquartered in Strängnäs, Sweden, SPM International develops and supplies advanced condition monitoring and process optimization solutions that help industries improve reliability, performance, and sustainability. With patented technologies, in-house R&D and production, the companies in the SPM Group and its partners deliver complete condition-based maintenance systems for process and heavy industry globally. The Group’s new entity, SPM Academy Inc., broadens this mission by providing ISO-certified vibration analysis training to maintenance and reliability professionals worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251103304953/en/
Contacts
Media contacts
Europe: Josefin Lindberg Roug, SPM International – info@spminstrument.se | +46
152 225 00
North America: Anna Aranha, SPM Academy Inc. – info@spmacademy.com |
1-239-508-1200
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom